[HTML][HTML] Development and validation of a renal risk score in ANCA-associated glomerulonephritis
SR Brix, M Noriega, P Tennstedt, E Vettorazzi… - Kidney international, 2018 - Elsevier
Predicting renal outcome in antineutrophil cytoplasmic antibody (ANCA)–associated
glomerulonephritis (GN) remains a major challenge. We aimed to identify reliable predictors of end-…
glomerulonephritis (GN) remains a major challenge. We aimed to identify reliable predictors of end-…
[PDF][PDF] Autoimmune renal disease is exacerbated by S1P-receptor-1-dependent intestinal Th17 cell migration to the kidney
CF Krebs, HJ Paust, S Krohn, T Koyro, SR Brix… - Immunity, 2016 - cell.com
Th17 cells are most abundant in the gut, where their presence depends on the intestinal
microbiota. Here, we examined whether intestinal Th17 cells contribute to extra-intestinal Th17 …
microbiota. Here, we examined whether intestinal Th17 cells contribute to extra-intestinal Th17 …
IL-33–mediated expansion of type 2 innate lymphoid cells protects from progressive glomerulosclerosis
…, M Becker, K Kopp, M Düster, SR Brix… - Journal of the …, 2017 - journals.lww.com
Innate lymphoid cells (ILCs) have an important role in the immune system's response to
different forms of infectious and noninfectious pathologies. In particular, IL-5–and IL-13–…
different forms of infectious and noninfectious pathologies. In particular, IL-5–and IL-13–…
CXCR3+ regulatory T cells control TH1 responses in crescentic GN
…, JH Riedel, CF Krebs, JE Turner, SR Brix… - Journal of the …, 2016 - journals.lww.com
Chemokines and chemokine receptors are implicated in regulatory T cell (Treg) trafficking to
sites of inflammation and suppression of excessive immune responses in inflammatory and …
sites of inflammation and suppression of excessive immune responses in inflammatory and …
Stat3 programs Th17-specific regulatory T cells to control GN
…, B Goerke, HJ Paust, SR Brix… - Journal of the …, 2014 - journals.lww.com
A pathogenic role for Th17 cells in inflammatory renal disease is well established. The
mechanisms underlying their counter-regulation are, however, largely unknown. Recently, Th17 …
mechanisms underlying their counter-regulation are, however, largely unknown. Recently, Th17 …
IL-17C/IL-17 receptor E signaling in CD4+ T cells promotes TH17 cell-driven glomerular inflammation
…, CF Krebs, JE Turner, SR Brix… - Journal of the …, 2018 - journals.lww.com
The IL-17 cytokine family and the cognate receptors thereof have a unique role in organ-specific
autoimmunity. Most studies have focused on the founding member of the IL-17 family, IL-…
autoimmunity. Most studies have focused on the founding member of the IL-17 family, IL-…
[PDF][PDF] Risk factors for severe outcomes in patients with systemic vasculitis and COVID‐19: a binational, registry‐based cohort study
…, S Gopaluni, D Gray, J Barrett, SR Brix… - Arthritis & …, 2021 - Wiley Online Library
Objective COVID‐19 is a novel infectious disease with a broad spectrum of clinical severity.
Patients with systemic vasculitis have an increased risk of serious infections and may be at …
Patients with systemic vasculitis have an increased risk of serious infections and may be at …
[HTML][HTML] Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies
S Irmscher, SR Brix, SLH Zipfel, LD Halder… - Nature …, 2019 - nature.com
Persistent inflammation is a hallmark of many human diseases, including anti-neutrophil
cytoplasmic antibody-associated vasculitis (AAV) and atherosclerosis. Here, we describe a …
cytoplasmic antibody-associated vasculitis (AAV) and atherosclerosis. Here, we describe a …
Risk stratification to predict renal survival in anti–glomerular basement membrane disease
Background Prospective randomized trials investigating treatments and outcomes in anti–glomerular
basement membrane (anti-GBM) disease are sparse, and validated tools to aid …
basement membrane (anti-GBM) disease are sparse, and validated tools to aid …
[HTML][HTML] Bevacizumab-associated glomerular microangiopathy
F Person, MM Rinschen, SR Brix, S Wulf… - Modern Pathology, 2019 - Elsevier
Bevacizumab is a humanized monoclonal IgG1 antibody, which neutralizes vascular endothelial
growth factor and is used for treating multiple cancer types. As a known and frequent …
growth factor and is used for treating multiple cancer types. As a known and frequent …